Abstract: PO0570
Treatment for CKD: A Systematic Literature Review and Population Comparison
Session Information
- CKD Clinical, Outcomes, and Trials - 2
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Garcia Sanchez, Juan Jose, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Thompson, Juliette C., Visible Analytics, Oxford, United Kingdom
- Scott, David Alexander, Visible Analytics, Oxford, United Kingdom
- Rao, Naveen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- SOrstadius, Elisabeth, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- James, Glen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Nolan, Stephen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Wittbrodt, Eric T., BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States
- Abdul Sultan, Alyshah, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Stefansson, Bergur V., BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Jackson, Dan, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Hawkins, Neil S., Visible Analytics, Oxford, United Kingdom
- Abrams, Keith R., Visible Analytics, Oxford, United Kingdom
Background
DAPA-CKD is the first renal outcomes trial assessing the efficacy and safety of a sodium–glucose cotransporter-2 inhibitor, dapagliflozin, vs placebo, added to standard of care in patients with chronic kidney disease (CKD) with/without type 2 diabetes (T2D). Several other agents have been or are currently under investigation for their effect on renal and cardiovascular outcomes in CKD; however, comparisons of efficacy are challenging, due to differences in study design, duration, patients and endpoint definitions. We conducted a systematic literature review of randomized controlled trials (RCTs) in CKD, with the aim of assessing inter-study comparability.
Methods
Searches of MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and grey literature sources were conducted to identify phase 3–4 RCTs of adults (≥18 years) with albuminuric CKD with/without T2D, published in English between 1990 and March 25, 2020. Studies of ≥12 weeks duration that reported clinical outcomes, adverse events, quality of life or patient-reported outcomes for pharmacologic CKD treatments were eligible for inclusion.
Results
Preliminarily, 13,451 unique citations were identified, and 204 full-text manuscripts were included after abstract screening (Figure). Data from 81 RCTs were included: 24, 39 and 18 in patients with CKD with/without T2D, CKD with T2D and CKD without T2D, respectively.
Conclusion
As anticipated, differences in the inclusion of patients with/without T2D between studies make comparisons difficult. Future work will compare additional relevant study characteristics, with further insights available in October 2020.
Figure: PRISMA diagram
Funding
- Commercial Support – AstraZeneca